Search results
Results From The WOW.Com Content Network
2,100. Website. www.alkermes.com. Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. [3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and ...
Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) delivered earnings and revenue surprises of 75.00% and -2.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Alkermes plc (NASDAQ:ALKS), with a market cap of US$5.3b, are often out of the spotlight. While ...
Automated lane keeping systems ( ALKS ), also described as traffic jam chauffeurs, [1] is an autonomous driving system that doesn't require driver supervision on motorways. ALKS is an international standard set out in UN-ECE regulation 157 and amounts to Level 3 vehicle automation. [2] It is essentially a more robust combination of adaptive ...
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
ALKS 2680 is in development for the treatment of narcolepsy. [8] In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nevaleukin alfa.